COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS A SECOND-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN THE UNITED STATES

被引：0
|
作者：
Chen, N. C. [1 ]
McQueen, R. [1 ]
机构：
[1] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE369
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [31] Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis
    Liu, Kun
    Zhu, Youwen
    Zhou, Yangying
    Zhu, Hong
    ADVANCES IN THERAPY, 2023, 40 (04) : 1838 - 1849
  • [32] Cost-Effectiveness Analysis of Empagliflozin as a Second-Line Therapy in Treatment Sequences of Patients With Type 2 Diabetes in The United States
    Reifsnider, Odette
    Kansal, Anuraag
    Pimple, Pratik
    Aponte-Ribero, Valerie
    Brand, Sarah
    Shetty, Sharash
    CIRCULATION, 2019, 140
  • [33] Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma
    Parikh, Neehar D.
    Singal, Amit G.
    Hutton, David W.
    CANCER, 2017, 123 (19) : 3725 - 3731
  • [34] Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma
    Kadono, Yoshifumi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Shigehara, Kazuyoshi
    Izumi, Kouji
    Kamijima, Taiki
    Seto, Chikashi
    Takano, Akinobu
    Yotsuyanagi, Satoshi
    Nakagawa, Ryunosuke
    Miyagi, Tohru
    Aoyama, Shuhei
    Asahi, Hideki
    Fukuda, Rie
    Mizokami, Atsushi
    ANTICANCER RESEARCH, 2021, 41 (03) : 1599 - 1606
  • [35] Expanding Immunotherapy Options for Bladder Cancer Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Lavoie, Jean-Michel
    Bidnur, Samir
    Black, Peter C.
    Eigl, Bernhard J.
    UROLOGY, 2017, 106 : 1 - 2
  • [36] Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer
    Lam, Simon W.
    Wai, Maya
    Lau, Jessica E.
    McNamara, Michael
    Earl, Marc
    Udeh, Belinda
    PHARMACOTHERAPY, 2017, 37 (01): : 94 - 103
  • [37] Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
    Reifsnider, Odette
    Pimple, Pratik
    Stargardter, Matthew J. D.
    Brand, Sarah
    Desai, Nihar
    Shetty, Sharash
    DIABETES, 2020, 69
  • [38] Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States
    Reifsnider, Odette
    Kansal, Anuraag
    Pimple, Pratik
    Aponte-Ribero, Valerie
    Brand, Sarah
    Shetty, Sharash
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 791 - 799
  • [39] Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States
    Criss, Steven D.
    Weaver, Davis T.
    Sheehan, Deirdre F.
    Lee, Richard J.
    Pandharipande, Pari V.
    Kong, Chung Yin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (03) : 180.e11 - 180.e18
  • [40] Immune Checkpoint Inhibition in Urothelial Carcinoma Pembrolizumab as a new Therapy Standard in Second-line Therapy?
    Oing, Christoph
    Bokemeyer, Carsten
    ONKOLOGE, 2017, 23 (08): : 678 - 679
12345